Table 3.
Univariable analysis of risk factors for admission.
| Characteristic | Required Admission, N = 511 | OR2 | 95% CI2 | p-value |
|---|---|---|---|---|
|
Cell Therapy Type
Allo |
14 (9.4%) | — | — | |
| Auto | 25 (15%) | 1.65 | 0.83, 3.39 | 0.2 |
| CART | 12 (44%) | 7.71 | 3.02, 20.0 | <0.001 |
|
| ||||
| Age at COVID-19 Diagnosis, years, median (IQR) | 64 (57, 71) | 1.03 | 1.00, 1.05 | 0.040 |
|
| ||||
|
Variant BA1 |
32 (16%) | — | — | |
| BA2 | 5 (15%) | 0.94 | 0.30, 2.45 | >0.9 |
| BA2.12.1 | 0 (0%) | NE3 | 3 | >0.9 |
| BA5/BA4 | 2 (3.8%) | 0.21 | 0.03, 0.73 | 0.037 |
| DELTA | 12 (24%) | 1.71 | 0.78, 3.57 | 0.2 |
|
| ||||
|
Gender Male |
28 (14%) | — | — | |
| Female | 23 (16%) | 1.19 | 0.65, 2.16 | 0.6 |
|
| ||||
|
Race White |
43 (15%) | — | — | |
| Asian/ Far East/ Indian | 6 (22%) | 1.56 | 0.55, 3.89 | 0.4 |
| Black/ African American | 1 (2.7%) | 0.15 | 0.01, 0.73 | 0.066 |
| Other | 1 (20%) | 1.37 | 0.07, 9.51 | 0.8 |
|
| ||||
|
Hematologic disease Acute/Chronic Leukemia |
11 (12%) | — | — | |
| Hodgkin Lymphoma | 0 (0%) | NE | >0.9 | |
| Myelodysplastic Syndrome | 1 (4.3%) | 0.33 | 0.02, 1.82 | 0.3 |
| Myeloproliferative Neoplasm | 1 (12%) | 1.03 | 0.05, 6.60 | >0.9 |
| Non-Hodgkin Lymphoma | 21 (23%) | 2.09 | 0.96, 4.79 | 0.069 |
| Plasma Cell Neoplasm | 17 (14%) | 1.16 | 0.52, 2.69 | 0.7 |
|
| ||||
| Smoking Status | 15 (16%) | 1.26 | 0.63, 2.41 | 0.5 |
|
| ||||
| antiCD20 Exposure | 0 (0%) | NE | >0.9 | |
|
| ||||
| ITK Exposure | 0 (0%) | NE | >0.9 | |
|
| ||||
| GVHD Immunosuprresants | 6 (9.7%) | 0.57 | 0.21, 1.31 | 0.2 |
|
| ||||
| Steroid | 16 (22%) | 1.92 | 0.97, 3.66 | 0.053 |
|
| ||||
| Hypogammaglobulinemia | 8 (30%) | 2.71 | 1.06, 6.40 | 0.027 |
|
| ||||
|
Comorbidity Total
0 |
12 (8.2%) | — | — | |
| 1 | 8 (8.1%) | 0.99 | 0.37, 2.49 | >0.9 |
| 2+ | 31 (31%) | 4.98 | 2.47, 10.7 | <0.001 |
|
| ||||
|
Time from HCT/CART to COVID-19, days (%) ≤ 100 |
9 (30%) | — | — | |
| 100 – 180 | 3 (12%) | 0.33 | 0.07, 1.30 | 0.13 |
| 181 – 365 | 7 (16%) | 0.45 | 0.14, 1.39 | 0.2 |
| 366 – 1095 | 13 (15%) | 0.42 | 0.16, 1.13 | 0.079 |
| ≥ 1096 | 19 (12%) | 0.31 | 0.12, 0.79 | 0.011 |
|
| ||||
| tixagevimab-cilgavimab exposure | 2 (9.5%) | 0.60 | 0.09, 2.14 | 0.5 |
|
| ||||
| Vaccinated | 40 (14%) | 0.67 | 0.33, 1.46 | 0.3 |
|
| ||||
| Full/Maintenance treatment | 22 (16%) | 1.19 | 0.65, 2.17 | 0.6 |
1
n (%); Median (IQR)
2
OR = Odds Ratio, CI = Confidence Interval
(NE) Non-Estimable; 0 patients required hospital admission
Auto: autologous stem cell transplantation. Allo: allogeneic stem cell transplantation. ITK: tyrosine-kinase inhibitors, GVHD: graft versus host disease.